Evidence map›Paper›PMID 36547748›Full record

ReviewCancer metastasis reviews2023

Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities.

Shant Qinxiang Sin, Chakrabhavi Dhananjaya Mohan, Robby Miguel Wen-Jing Goh, Mingliang You, Siddaiah Chandra Nayak, Lu Chen, Gautam Sethi, Kanchugarakoppal Subbegowda Rangappa, Lingzhi Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer metastasis reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Understanding how hypoxia contributes to liver cancer stem cells maintenance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Shant Qinxiang Sin *Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Chakrabhavi Dhananjaya Mohan *Department of Studies in Molecular Biology, University of Mysore, Manasagangotri, Mysore, 570006, India.
Robby Miguel Wen-Jing Goh *Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Mingliang YouKey Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou Cancer Institute, Hangzhou, 31002, China.
Siddaiah Chandra NayakDepartment of Studies in Biotechnology, University of Mysore, Manasagangotri, Mysore, 570006, India.
Lu ChenCollege of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Gautam SethiNUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Kanchugarakoppal Subbegowda RangappaInstitution of Excellence, Vijnana Bhavan, University of Mysore, Manasagangotri, Mysore, 570006, India. rangappaks@yahoo.com.ORCID 0000-0003-0572-6305
Lingzhi WangCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. csiwl@nus.edu.sg.
National University of Singapore · SGUniversity of Mysore · INChengdu University of Traditional Chinese Medicine · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers with a relatively high cancer-related mortality. The uncontrolled proliferation of HCC consumes a significant amount of oxygen, causing the development of a hypoxic tumor microenvironment (TME). Hypoxia-inducible factors (HIFs), crucial regulators in the TME, activate several cancer hallmarks leading to the hepatocarcinogenesis of HCC and resistance to current therapeutics. As such, HIFs and their signaling pathways have been explored as potential therapeutic targets for the future management of HCC. This review discusses the current understanding of the structure and function of HIFs and their complex relationship with the various cancer hallmarks. To address tumor hypoxia, this review provides an insight into the various potential novel therapeutic agents for managing HCC, such as hypoxia-activated prodrugs, HIF inhibitors, nanomaterials, antisense oligonucleotides, and natural compounds, that target HIFs/hypoxic signaling pathways in HCC. Because of HCC's relatively high incidence and mortality rates in the past decades, greater efforts should be put in place to explore novel therapeutic approaches to improve the outcome for HCC patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsCell HypoxiaCell Line, TumorHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitSignal TransductionTumor MicroenvironmentHypoxia-Inducible Factor 1, alpha SubunitHepatocellular carcinomaHypoxia signalingTherapeuticsTumor microenvironment

Identifiers

PMID36547748
OpenAlexW4312093743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.